Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 19.10.2021.

#ECTRIMS2021
#RocheInnovation
#earlystage
#MEDIA
#InvestmentCall
#NMOSD
#lymsm
#startup
#lymphoma
#multiplesclerosis

Healthcare

@BIODeutschland shared
On Oct 18, 2021
RT @ITM_Radiopharma: Together with CNL, we announced the signing of a Memorandum of Understanding to explore the development & industrial-scale production of Actinium-225, a rare medical radioisotope with high potential for cancer treatment. Read more at https://t.co/cjZ4C8oeIQ https://t.co/1Q6kADUOpY
Open
ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Garching/Munich, Germany and Chalk River, Ontario, Canada – October 18, 2021 – ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Canadian …

@The_NHSA shared
On Oct 13, 2021
RT @health_foundry: 2 DAYS TO GO ‼️ #InvestmentCall 🗣️ Are you an #earlystage #startup seeking investment? Join us for a FREE event in partnership with @MedCityHQ, @QMEnterprise and @wmahsn on an exciting new joint investment call from Medcity and @CapitalSpex ⏬ https://t.co/8O8shlsp9y
Open
Lunch&Learn: Spex Capital and MedCity Healthtech Investment Call

Lunch&Learn: Spex Capital and MedCity Healthtech Investment Call

Join us for an event in partnership with Medcity, QME and WMAHSN on a new joint investment call from Medcity and Spex Capital.

@BIODeutschland shared
On Oct 15, 2021
RT @Roche: #MEDIA - We are pleased to announce a collaboration with @Path_AI to bring the latest AI-powered technology to pathologists. Expanded access to digital diagnostic tools unlocks new opportunities to improve patient outcomes. https://t.co/J5Bdbk2TKf $ROG $RHHBY https://t.co/S1VIHNLNKX
Open
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs. Builds on Roche’s Digital …

@BIODeutschland shared
On Oct 14, 2021
RT @Roche: New data released at #ECTRIMS2021 demonstrates longer term efficacy of our medicine in preventing life changing relapses in people with neuromyelitis optica spectrum disorder, a rare, lifelong and debilitating disease. #NMOSD $RHHBY $ROG https://t.co/de4zvBo4Li https://t.co/mTQ1BPmZbU
Open
New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder

New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder

New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of …

@BIODeutschland shared
On Oct 14, 2021
RT @Roche: A shorter 90-minute infusion time of Roche’s medicine is approved in Europe for previously treated or untreated advanced follicular #lymphoma, which could improve patient experience by reducing time spent in hospital. https://t.co/KIDjr7yVgb $RHHBY $ROG #RocheInnovation #lymsm https://t.co/h8H1oFpzMg
Open
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately …

@BIODeutschland shared
On Oct 13, 2021
RT @Roche: We’re proud to announce new data at #ECTRIMS2021 showing the importance of early and ongoing treatment to reduce disability progression in relapsing and primary progressive #multiplesclerosis: https://t.co/iqKKQ7xxjb $ROG $RHHBY https://t.co/OPU0mMnoel
Open
Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) 29% …

@BIODeutschland shared
On Oct 15, 2021
RT @EBDgroup: Biopharma companies in Europe have witnessed a surge in partnership activity as the life sciences sector has risen to meet the challenges presented by Covid-19. Take a look inside some of those European innovators >> https://t.co/T4LBFTejhO Article by @MCServicesAG
Open
Fuelling the Rise of European Innovation: Advances in Biotech Partnering

Fuelling the Rise of European Innovation: Advances in Biotech Partnering

Examples of this can be seen in the life sciences division of the French private equity firm, Andera Partners, German VC investor MIG Capital and the Family Office of Andreas and …

@SensyneHealth shared
On Oct 13, 2021
Partnership models allowing #AI analysis of de-identified #patientdata and ethical data sharing practices can bring improvements in #patientcare and accelerate development of new medicines while protecting #patient information.  Read more here: https://t.co/NjkQLE8GHg
Open
The need for ethical data models for comprehensive data sharing

The need for ethical data models for comprehensive data sharing

It is imperative for health systems to form data sharing partnerships that allow for the analysis of de-identified clinical data, while effectively and comprehensively protecting patient ...